百济神州(ONC.US)盘前涨超3%,报324.4美元;该股昨日收跌超10%。高盛发表报告表示,纽约时报称,美国总统特朗普的政府正讨论限制中国药品,并草拟一份行政命令(EO),旨在通过多项措施限制中国原创新药进入美国市场。这一消息就潜在短期股价风险而言,预计对百济神州、传奇生物等已具备全球布局的企业影响有限,因这类公司已在美国等市场建立稳固根基,市场对其新增交易预期较低。
百济神州(ONC.US)盘前涨超3%,报324.4美元;该股昨日收跌超10%。高盛发表报告表示,纽约时报称,美国总统特朗普的政府正讨论限制中国药品,并草拟一份行政命令(EO),旨在通过多项措施限制中国原创新药进入美国市场。这一消息就潜在短期股价风险而言,预计对百济神州、传奇生物等已具备全球布局的企业影响有限,因这类公司已在美国等市场建立稳固根基,市场对其新增交易预期较低。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.